Forest Laboratories (NYSE: FRX) and Neuralstem (NASDAQ:CUR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation and institutional ownership.


This table compares Forest Laboratories and Neuralstem’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Forest Laboratories N/A N/A N/A
Neuralstem -198,573.91% -321.78% -127.53%

Valuation & Earnings

This table compares Forest Laboratories and Neuralstem’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Forest Laboratories N/A N/A N/A N/A N/A
Neuralstem $16,246.00 842.80 -$18.67 million N/A N/A

Forest Laboratories has higher revenue, but lower earnings than Neuralstem.

Analyst Recommendations

This is a summary of recent ratings and price targets for Forest Laboratories and Neuralstem, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Forest Laboratories 0 0 0 0 N/A
Neuralstem 0 0 3 0 3.00

Neuralstem has a consensus target price of $2.79, indicating a potential upside of 147.20%. Given Neuralstem’s higher possible upside, analysts clearly believe Neuralstem is more favorable than Forest Laboratories.

Institutional & Insider Ownership

7.3% of Neuralstem shares are held by institutional investors. 15.4% of Neuralstem shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


Neuralstem beats Forest Laboratories on 5 of the 8 factors compared between the two stocks.

Forest Laboratories Company Profile

Forest Laboratories, Inc. (Forest), develops, manufactures and sells branded forms of ethical drug products, which requires a physician’s prescription. The Company’s products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer’s type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD). In February 2014, it acquired Aptalis. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.

Neuralstem Company Profile

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Receive News & Ratings for Forest Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forest Laboratories Inc. and related companies with's FREE daily email newsletter.